Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sidebar: Obesity: Three New Drug Candidates Promise A New Dawn

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

Executive Summary

Arena is positioning its pending anti-obesity NME lorcaserin as the cure for the obesity market hangover induced by the troublesome side effect profiles associated with earlier Rx weight loss products.

You may also be interested in...



Weighing Obesity Risk: FDA, EMEA Use Different Scales For Abbott's Meridia

Abbott is withdrawing its anti-obesity drug sibutramine from the European Union markets at the urging of the European Medicines Agency

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals

Product

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: CAR-T Malignancy Reports, Background Music In DTC Ads, New No. 2 At US FDA

‘Vast Amount Of Valuable Input’ Leads Australia To Extend HTA Review

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

See All
UsernamePublicRestriction

Register

PS004382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By